The Prognosis of Hepatocellular Carcinoma Treated with Sorafenib in Combination with TACE.

ABSTRACT:

Objective

Sorafenib have been shown to be effective in the treatment of advanced HCC and has been standard therapy since its release in Japan in 2009 (Llovet et al., 2008; Cheng et al., 2009). However, due to a low response rate, more aggressive combination treatment has been utilized as a multimodal strategy. The present study aimed to determine the efficacy of sorafenib alone and in combination with transarterial chemoembolization (TACE) for the treatment of advanced HCC.

Methods

All patients with unresectable advanced HCC who were prescribed sorafenib at Kanto Rosai Hospital were included in the study. Five-year overall survival (OS) rates were estimated for patients treated with sorafenib alone or in combination with TACE. Multivariate and univariate regression analyses

SUBMITTER: Kimura Y 

PROVIDER: S-EPMC7568902 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature